Newsroom press releases

06/05/25 - 17:41

Revenue growing +8% and EBITDA margin at 34%: Q1 Results confirm FY 2025 Guidance (268.56 KB)

Financial Data

Download

28/04/25 - 16:50

Shareholders' Meeting 2025 (138.81 KB)

Other

Download

18/04/25 - 18:11

Diasorin receives 510(k) clearance for its second multiplex molecular panel for diagnosing bloodstream infections on LIAISON PLEX® (161.29 KB)

Products

Download

07/04/25 - 13:07

Publication of the lists of candidates for the appointment of the Board Directors, the Board of Statutory Auditors and relevant proposals for resolution. (111.09 KB)

Financial Disclosures

Download

04/04/25 - 0:59

Notice pursuant to art. 144-octied, para. 2 of CONSOB regulation No. 1971/1999 (125.78 KB)

Other

Download

31/03/25 - 19:36

Adoption of the enhancement of the increased voting rights mechanism: withdrawal exercised by 1.69% of the share capital. Statutory option and pre-emption offer period to start on 31 March 2025. (119.78 KB)

Other

Download

18/03/25 - 11:54

Diasorin launches the Simplexa™ C. auris direct assay on the LIAISON® MDX instrument in all countries accepting the CE Mark (126.65 KB)

Products Molecular

Download

14/03/25 - 16:29

The Board of Directors of Diasorin SpA approves FY2024 Results with revenues and net profit in expansion compared to Previous Year; Proposed Ordinary Dividend of € 1.20 per share (239.79 KB)

Financial Data

Download

03/03/25 - 21:19

Registration and publication the minutes of shareholders' meeting. Withdrawal right. (101.04 KB)

Other

Download

03/03/25 - 21:05

Notice to Shareholders - Information regarding the exercise of the withdrawal right (88.54 KB)

Other

Download

28/02/25 - 11:49

The Extraordinary Meeting of Shareholders approves the enhancement of the increased voting rights mechanism (111.6 KB)

Other

Download

27/01/25 - 20:14

Proposal to enhance the increased voting rights mechanism to support the Company's growth strategy, also by external lines, and reward a shareholder base with a long-term investment horizon (126.5 KB)

Other

Download

20/12/12 - 1:00

Shareholders' meeting (55.42 KB)

Financial Data

Download

07/11/12 - 1:00

The BoD approves Q3'12 results (280.42 KB)

Financial Data

Download

03/08/12 - 2:00

The BoD approves H1'12 results (279.41 KB)

Financial Data

Download

30/07/12 - 2:00

DiaSorin in India: JV with Trivitron Healthcare (56.16 KB)

Acquisition / Partnership

Download

27/06/12 - 2:00

Notification of changes in share capital (335.97 KB)

Financial Data

Download

11/05/12 - 2:00

The BoD approves Q1'12 results (122.04 KB)

Financial Data

Download

04/05/12 - 2:00

NorDiag acquisition (88.87 KB)

Acquisition / Partnership

Download

23/04/12 - 2:00

2011 statutory financial statement approval (182.29 KB)

Financial Data

Download

10/04/12 - 2:00

Measles and Mumps IgM on LIAISON (available outside the US and Canada only) (43.59 KB)

Products Immunodiagnostic

Download

02/04/12 - 2:00

Helicobacter Pylori on stool on LIAISON (available outside the US and Canada only) (43.85 KB)

Products Immunodiagnostic

Download

30/03/12 - 2:00

Financial calendar update (176.51 KB)

Financial Data

Download

22/03/12 - 1:00

Stock options to employees (175.38 KB)

Financial Data

Download

12/03/12 - 1:00

Agreement with Sonic Healthcare on Vitamin D (179.85 KB)

Acquisition / Partnership

Download

09/03/12 - 1:00

The BoD approves FY 2011 results (357.11 KB)

Financial Data

Download

07/03/12 - 1:00

Notification of changes in share capital (46.84 KB)

Financial Data

Download

17/02/12 - 1:00

DiaSorin became a member of the ISBT (178.96 KB)

Acquisition / Partnership

Download

09/02/12 - 1:00

Notice of change in share capital (46.97 KB)

Financial Data

Download

02/02/12 - 1:00

FDA clearance for 25 OH Vitamin D on LIAISON (180.35 KB)

Products Immunodiagnostic

Download

27/01/12 - 1:00

2012 Financial calendar update (177.74 KB)

Financial Data

Download

25/01/12 - 1:00

Dividend distribution in June (115.61 KB)

Financial Data

Download

19/01/12 - 1:00

Prize for best Italian Company in R&D in the UK (183.95 KB)

Other

Download

13/01/12 - 1:00

2012 Financial calendar (176.51 KB)

Financial Data

Download

12/01/12 - 1:00

New anti HBs II (available outside the US and Canada only) (196.83 KB)

Products Immunodiagnostic

Download

Newsroom press releases

Select year

Newsroom press category

Revenue growing +8% and EBITDA margin at 34%: Q1 Results confirm FY 2025 Guidance (268.56 KB)

Shareholders' Meeting 2025 (138.81 KB)

Diasorin receives 510(k) clearance for its second multiplex molecular panel for diagnosing bloodstream infections on LIAISON PLEX® (161.29 KB)

Publication of the lists of candidates for the appointment of the Board Directors, the Board of Statutory Auditors and relevant proposals for resolution. (111.09 KB)

Notice pursuant to art. 144-octied, para. 2 of CONSOB regulation No. 1971/1999 (125.78 KB)

Adoption of the enhancement of the increased voting rights mechanism: withdrawal exercised by 1.69% of the share capital. Statutory option and pre-emption offer period to start on 31 March 2025. (119.78 KB)

Diasorin launches the Simplexa™ C. auris direct assay on the LIAISON® MDX instrument in all countries accepting the CE Mark (126.65 KB)

The Board of Directors of Diasorin SpA approves FY2024 Results with revenues and net profit in expansion compared to Previous Year; Proposed Ordinary Dividend of € 1.20 per share (239.79 KB)

Registration and publication the minutes of shareholders' meeting. Withdrawal right. (101.04 KB)

Notice to Shareholders - Information regarding the exercise of the withdrawal right (88.54 KB)

The Extraordinary Meeting of Shareholders approves the enhancement of the increased voting rights mechanism (111.6 KB)

Proposal to enhance the increased voting rights mechanism to support the Company's growth strategy, also by external lines, and reward a shareholder base with a long-term investment horizon (126.5 KB)

Shareholders' meeting (55.42 KB)

The BoD approves Q3'12 results (280.42 KB)

The BoD approves H1'12 results (279.41 KB)

DiaSorin in India: JV with Trivitron Healthcare (56.16 KB)

Notification of changes in share capital (335.97 KB)

The BoD approves Q1'12 results (122.04 KB)

NorDiag acquisition (88.87 KB)

2011 statutory financial statement approval (182.29 KB)

Measles and Mumps IgM on LIAISON (available outside the US and Canada only) (43.59 KB)

Helicobacter Pylori on stool on LIAISON (available outside the US and Canada only) (43.85 KB)

Financial calendar update (176.51 KB)

Stock options to employees (175.38 KB)

Agreement with Sonic Healthcare on Vitamin D (179.85 KB)

The BoD approves FY 2011 results (357.11 KB)

Notification of changes in share capital (46.84 KB)

DiaSorin became a member of the ISBT (178.96 KB)

Notice of change in share capital (46.97 KB)

FDA clearance for 25 OH Vitamin D on LIAISON (180.35 KB)

2012 Financial calendar update (177.74 KB)

Dividend distribution in June (115.61 KB)

Prize for best Italian Company in R&D in the UK (183.95 KB)

2012 Financial calendar (176.51 KB)

New anti HBs II (available outside the US and Canada only) (196.83 KB)

Price Sensitive